Cell and gene therapies are a transformative approach that provides new therapeutic options for patients with cancer, immune disorders, hemophilia, and other conditions. However, these therapies present fundamental challenges for payers seeking to balance access, cost, and affordability.
During a session at AMCP Nexus 2020 Virtual, Brian Corvino, MBA, managing director, and Jennifer Sturm, MBA, senior manager, both of Deloitte, discussed the need for innovative payment models, benefit design, utilization management, and value assessment to ensure access to these therapies is cost-effective and sustainable. Read more here.
(Source: Kerri Fitzgerald; AMCP Nexus; November 5, 2020)